Sarepta Therapeutics, Inc.
General ticker "SRPT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.1B (TTM average)
Sarepta Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -0.0%.
Estimated limits based on current volatility of 4.8%: low 20.75$, high 22.83$
Factors to consider:
- Total employees count: 1372 (+4.4%) as of 2024
- US accounted for 43.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Manufacturing risks, Labor/talent shortage/retention, Regulatory and compliance, IP infringement, Insufficient capital
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [13.79$, 35.50$]
- 2026-12-31 to 2027-12-31 estimated range: [14.45$, 36.03$]
Financial Metrics affecting the SRPT estimates:
- Negative: with PPE of -2.7 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -9.00 <= 0.28
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 3.05 > -0.64
- Positive: Inventory ratio change, % of -6.92 <= -0.75
- Positive: Interest expense per share per price, % of 0.43 <= 0.75
Short-term SRPT quotes
Long-term SRPT plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $1,243.34MM | $1,901.98MM | $2,198.24MM |
| Operating Expenses | $1,511.16MM | $1,683.90MM | $2,898.02MM |
| Operating Income | $-267.82MM | $218.08MM | $-699.78MM |
| Non-Operating Income | $-252.27MM | $42.69MM | $-2.44MM |
| Interest Expense | $22.01MM | $18.39MM | $9.73MM |
| R&D Expense | $877.39MM | $804.52MM | $1,522.07MM |
| Income(Loss) | $-520.10MM | $260.77MM | $-702.23MM |
| Taxes | $15.88MM | $25.54MM | $11.19MM |
| Net Income(Loss)* | $-535.98MM | $235.24MM | $-713.41MM |
| Stockholders Equity | $859.34MM | $1,527.74MM | $1,140.62MM |
| Inventory | $322.86MM | $749.96MM | $914.74MM |
| Assets | $3,264.58MM | $3,963.17MM | $3,349.70MM |
| Operating Cash Flow | $-500.99MM | $-205.79MM | $-205.48MM |
| Capital expenditure | $87.34MM | $146.96MM | $101.97MM |
| Investing Cash Flow | $-165.80MM | $755.56MM | $69.64MM |
| Financing Cash Flow | $125.00MM | $124.81MM | $-168.34MM |
| Earnings Per Share** | $-5.80 | $2.47 | $-6.81 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.